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THE ETHICS OF RESEARCH RELATED TO
HEALTHCARE IN DEVELOPING COUNTRIES
Keith McAdam*
Abstract: In April 2002 the Nuffield Council on Bioethics published the Report The Ethics of Research Related to
Healthcare in Developing Countries. It provides an ethical framework for those designing or conducting healthcare-
related research in developing countries. This paper will draw on the conclusions made in the Report, and present some
of the recommendations. It will cover the importance of genuine consent, standards of care and ethical review of
research. The focus will be on what happens when research is over and benefits to the community. The Report concludes
that rigorous safeguards must be in place to prevent the exploitation of those who take part in externally-sponsored
research.
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LA ÉTICA DE LA INVESTIGACIÓN RELACIONADA CON LA ATENCIÓN DE
SALUD EN LOS PAÍSES EN DESARROLLO
Resumen: En Abril del 2002, el Nuffield Council on Bioethics publicó el Informe sobre la ética de la investigación
relativa al cuidado de la salud en países en desarrollo, que proporciona una base ética para quienes diseñan o realizan
investigación en salud en estos países. Este artículo se basa en las conclusiones de este informe y presenta algunas de
las recomendaciones. Cubre la importancia del consentimiento informado genuino, estándares del cuidado de la salud
y evaluación ética de la investigación. Se enfoca en lo que sucede cuando la investigación finaliza y en los beneficios
para la comunidad. El informe concluye que se debe disponer de una rigurosa protección para prevenir la explotación
de aquellos que participan en una investigación patrocinada externamente.
Palabras clave: Consentimiento informado, ética, investigación, beneficios para la comunidad
A ÉTICA DA PESQUISA RELACIONADA COM O CUIDADO DE SAÚDE NOS
PAÍSES EM DESENVOLVIMENTO
Resumo: Em abril de 2002, o Nuffield Council on Bioethics publicou o Informe sobre a ética da pesquisa relacionada
ao cuidado da saúde em países em desenvolvimento. Este Informe nos oferece uma base ética para quem realiza
pesquisa em saúde nos países em desenvolvimento. Este artigo se baseia nas conclusões deste informe e apresenta
algumas das recomendações. Abarca a importância do consentimento informado genuíno, standards de cuidado de
saúde e avaliação ética da pesquisa. Enfoca o que acontece quando a pesquisa termina e nos benefícios para a comunidade.
O informe conclui que deve-se dispor de uma rigorosa proteção para  prevenir a explotação dos participantes da pesquisa
com patrocínio do exterior.
Palavras chave: Consentimento informado, ética, pesquisa, benefícios para a comunidade
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The Nuffield Council on Bioethics is an in-
dependent body that examines ethical questions
raised by recent advances in biological and
medical research.  The Council seeks to play a
role in contributing to policy-making and stimu-
lating debate in bioethics. Established in 1991,
the Council is funded by the Nuffield Founda-
tion, the UK Medical Research Council and the
Wellcome Trust1.
In February 1999 the Council held an inter-
national workshop on the ethics of clinical re-
search in developing countries. This workshop
was set up partly in response to recent interna-
tional controversies surrounding HIV research
in Thailand and Africa. There has also been a
significant increase in the amount of externally-
sponsored research related to healthcare in de-
veloping countries. Many of the issues raised
by such research, such as the kind of treatment
that should be provided to participants follow-
ing a trial, are not confined to research in de-
veloping countries. They tend, however, to be
exacerbated when only very limited resources
are available, as may be the case in developing
countries where basic healthcare is not widely
available and research ethics committees are
often underdeveloped or absent.
The workshop led to the publication of a
discussion paper. The Council then decided that
the topic was a matter of such importance that
a Working Party should be established to con-
sider it in more detail. The Working Party,
chaired by Professor Sir Ken Calman, had a
global perspective with members drawn from
a number of countries, including Ghana,
Uganda, The Gambia, India, Brazil, Denmark
and the UK.  The group, of which I was a mem-
ber, met nine times over 21 months, and held
several fact-finding meetings, in India, the
United States, and at an international meeting
in Oxford.  We also held a public consultation
exercise, during which we received 70 re-
sponses from 20 different countries.
The terms of reference of the Working Party
were to review the importance of externally-
sponsored research in developing countries, and
to identify and consider the ethical and social
implications of conducting such research. This
included discussing who benefits from the re-
search; consent; differences in cultural values;
differences in levels of healthcare between
countries; compatibility of ethical guidelines
produced by international bodies; the respec-
tive responsibilities of local and non-local eth-
ics review bodies and mechanisms for review
and monitoring; and follow-up, including the
possible implementation of findings, after the
completion of research.
The resulting Report, The Ethics of Research
Related to Healthcare in Developing Countries,
was published in April 20022. I am going to
present today some of the recommendations and
main conclusions that we reached.
Developing countries urgently need re-
search to help relieve the enormous burden of
disease they carry, including diseases such as
TB and malaria.  But many countries have lim-
ited funds and a lack of trained staff to con-
duct their own research.  Each year £35-40
billion is spent on healthcare research world-
wide but only 10% of this sum is devoted to
the health problems of 90% of the world’s
population. It is vital that both the public and
private sectors in developed countries should
1 The Nuffield Council has published eight major reports on
ethical issues associated with: genetic screening; ownership
of tissue; xenotransplantation; genetics and mental disorders;
genetically modified crops; research related to healthcare in
developing countries; genetics and human behaviour, and
pharmacogenetics. The Council has also published two
discussion papers dealing with ethical issues raised
respectively by research on human stem cells and the
patenting of DNA.
2 The report is available from the Council’s website:
www.nuffieldbioethics.org
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sponsor research to help bridge the gap. How-
ever, external sponsors differ in their motives
for conducting research in developing coun-
tries. It is therefore important that all coun-
tries set their own national priorities for re-
search into healthcare. When externally-spon-
sored research is proposed which falls outside
national priorities, its relevance must be justi-
fied to the appropriate research ethics com-
mittees.
Inequalities in resources, between external
sponsors and those in developing countries, will
often be so great that there is a real risk of ex-
ploitation.  One of the main conclusions of the
Report was that there must be rigorous safe-
guards in place to protect vulnerable individu-
als and communities who take part in exter-
nally-sponsored research. We realised it would
be impossible to formulate a robust set of guide-
lines for all situations, because local and cul-
tural contexts must also be taken into account.
However, our recommendations provide an
ethical framework for anyone who is design-
ing or conducting research in developing coun-
tries. We have tried to identify the minimum
requirements which must be met in all circum-
stances.
The ethical framework used in the Report is
based on four principles: the duty to alleviate
suffering; the duty to show respect for persons,
the duty to be sensitive to cultural differences;
and the duty not to exploit the vulnerable. It is
crucial that these duties are respected when re-
search is planned and conducted. But when
applying these principles it is also critically
important that social, cultural and economic
context should also be taken into account.
There is no shortage of national and inter-
national guidelines that regulate the conduct of
healthcare research, including the WMA’s Dec-
laration of Helsinki and the CIOMS Interna-
tional Ethical Guidelines for Biomedical re-
search involving Human Subjects among many.
However, in practice, researchers and sponsors
are confronted with guidance that is often
generalised and sometimes ambiguous. We con-
sidered it important to encourage countries to
produce their own national guidance for the
clear application of international codes and
regulations.  More specifically, any new or re-
vised guidance should require the provision of
training in the ethical conduct of research for
all professionals involved. Training in interpret-
ing and applying research guidance is an im-
portant accompaniment to the guidance itself.
We identified a number of pressing issues
in the planning of externally-sponsored re-
search. These included consent, standards of
care, ethical review of research and what hap-
pens when research is over.  I will turn to each
of these briefly now, before focusing on the
question of what should happen after the re-
search is over and the community benefits of
research.
Genuine consent
Misunderstandings can occur when sponsors
of research are unfamiliar with the cultural tra-
ditions of the country in which it is conducted.
Researchers are often faced with difficult choices
when considering who should make decisions
about taking part in the research. For example,
in some communities it is customary for senior
members of the family to make decisions on
behalf of wives and children. It is crucial to be
sensitive to cultural differences, and the Work-
ing Party therefore recommended that in some
cultural contexts it may be necessary to obtain
agreement from the particular community or
assent from a senior family member, before any
prospective participant in research is approached.
However, there is also a duty to show respect
for persons, and it is therefore important to in-
sist that each participant must also individually
consent to take part. The ethically significant
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requirement is that consent must be genuine,
which means that it must be both voluntary and
informed. Health professionals must do their best
to communicate information accurately and in
an understandable and appropriate way. Infor-
mation forms which are long, complex and in-
appropriate for the cultural context are more
likely to confuse than to inform.
We must also recognise that in some situa-
tions it may be inappropriate to ask participants
to sign consent forms. An obvious example is
if research is being conducted in an illiterate
population. In these circumstances, participants
could be asked to give verbal consent. Re-
searchers should also consider an appropriate
procedure for witnessing the consent. The con-
sent process and information to be provided
should always be approved by a research eth-
ics committee.
Participants in research in developing and
developed countries have a range of motivations
for taking part in research. The point at which
inducements become inappropriate is not always
clear. Participants should, at the very least, not
be placed in a worse position by participating in
research. We suggested that, when assessing the
acceptability of inducements, researchers should
pay particular attention to the potential risks to
the participants’ health from taking part in the
research; whether the incentive being offered is
in proportion to the risks and costs to the partici-
pants; and whether guaranteeing substantial ben-
efits for taking part in research is more likely to
constitute an undue inducement because pro-
spective participants are especially vulnerable.
Decisions will need to be justified to local re-
search ethics committees.
Standards of care
A particularly controversial issue, which has
prompted international debate, concerns the
standard of care that is provided to members of
a control group during research. The Working
Party recommended that wherever appropriate,
participants in the control group should be of-
fered a universal standard of care. This term
refers to the best treatment available anywhere
in the world, by contrast with non-universal
standard of care, referring to treatment avail-
able in a defined region. However, there might
be cases where provision of a universal stan-
dard is not appropriate.  It may not always be
deliverable –if the universal standard of care
was a liver transplant, for example. Alterna-
tively, the use of a universal standard of care
may not give relevant results.  It may not, for
instance, be appropriate to evaluate a new treat-
ment against one that is too expensive to pur-
chase and too complicated to deliver in a par-
ticular country. There can also be cases where
the treatment being evaluated may be much
more effective than the currently available treat-
ment, but where this might not be demonstrated
by research using the universal standard for the
control group. In these instances, the challenge
is to fulfil the duty to undertake research in a
way that is consistent with the principle of not
exploiting those who are vulnerable. We rec-
ommended that the minimum that should be
offered to research participants is the best in-
tervention currently available as part of the na-
tional public health system. In certain well con-
sidered situations, exceptions to this recommen-
dation may be justified, for example where re-
search attempts to establish the ineffectiveness
of what currently is deemed to be the best treat-
ment available through the host’s country health
system, by comparing it to a placebo.
In determining the appropriate standard of
care to be provided to participants, the Work-
ing Party recommended that a number of fac-
tors be considered by sponsors, researchers and
research ethics committees. These include:
• the appropriate research design to answer
the research question,
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• the seriousness of the disease and the effect
of proven treatments,
• the existence of a universal standard of care
for the disease,
• the standard of care in the host and
sponsoring countries,
• the standard of care which can be afforded
by the host and sponsoring country for the
disease being studied,
• the standard of care which can effectively
be delivered in the host country during
research, and
• the standard of care which can be provided
in the host country on a sustainable basis.
Ethical review of research
Effective ethical review of research pro-
vides a crucial safeguard for research partici-
pants, and all countries should establish an
effective system. We recommended that ex-
ternally-sponsored research projects must be
reviewed locally. Funders should ensure that
the study they are funding has been reviewed
by a sufficiently diligent process, which as-
sesses the scientific validity and ethical accept-
ability, as well as the relevance to priorities in
healthcare within the country. Committees
which do not have adequate funding to cover
their costs may set fees for review. However,
it is vital that the independence of research
ethics committees be maintained. We there-
fore emphasised the need for creative ap-
proaches to providing support, without com-
promising their independence. We recom-
mended that all sponsors should be respon-
sible for meeting the costs of reviewing exter-
nally-sponsored research and that they should
ensure that the funds are used in an ethically
acceptable way.
What happens once the research is over?
Many controversies concern the question of
what happens when research is over. Is it ethi-
cally acceptable to conduct research into a form
of treatment in a country that may not be able
to afford to provide it? This is not a straightfor-
ward issue. For example, the price of treatments
can drop dramatically after research, or an
agreement may be reached with a pharmaceu-
tical company that the treatment will be pro-
vided for free for a certain period.
Researchers, sponsors and research ethics
committees have to consider whether a success-
ful intervention should be provided to three
groups of people: members of the control group
in a trial, all of the participants in the research
project, and the wider community in which the
research took place. The principle that those in
the control arm of a trial should be provided
with the intervention when it has been demon-
strated to be efficacious is widely acknowl-
edged. We also concluded that it is not ethi-
cally acceptable for any study to begin without
a decision having been made about whether or
not those in control groups will be offered an
intervention shown to be successful on comple-
tion of the trial, where relevant and appropri-
ate. Participants should be informed of the de-
cision as part of the process of obtaining their
consent.
With regards the provision of an interven-
tion to all participants once a study is over, the
revised Helsinki Declaration states that every
participant should be assured of access to the
best proven prophylactic, diagnostic and thera-
peutic methods that have been identified in the
study. There has been continued debate over
this and the WMA have set up a Working Party
to consider it further. However, guaranteeing
the provision of an intervention may not always
be possible, especially in relation to treatment
for chronic disease. We emphasised that it is
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important that the issues be considered at the
planning stage of any research, rather than de-
bated or negotiated at the end of the study. We
suggest that researchers should endeavour, be-
fore the beginning of a trial, to secure post-trial
access for effective interventions for all par-
ticipants.
A most contentious issue is the availability
of successful interventions to the wider com-
munity once research is over. Several questions
arise, with respect to the range and scope of
the responsibilities, and on whom such respon-
sibilities fall:
• Should provision of an effective treatment
be limited to the participants in research, or
extended to others in the wider community
after research? If the latter, by whom?
• How effective must an intervention be
shown to be to merit provision?
• Should all with a perceived need in the
country receive the intervention? If so, for
how long and who should provide it?
Many social, political and economic factors
will influence the likely availability of a treat-
ment shown to be successful and not all of these
can be anticipated. It is also important to re-
member that, in reality, a single research study
will only rarely lead to the discovery of a new
intervention that can be introduced promptly
into routine care. There is also likely to be a
need for further research to define the place of
the new intervention in the healthcare system
and the feasibility of introducing it. The trial
may need to be repeated elsewhere and in a dif-
ferent setting. However, the issue of whether a
new treatment could be introduced and main-
tained in the wider community should be con-
sidered before research is conducted, and there
will need to be negotiations between the vari-
ous interested parties.
Researchers have some responsibility in
these discussions but there is disagreement
about how far that responsibility extends. Re-
searchers are generally not in a position to trans-
late their findings into action. However, they
can draw attention to problems which have been
neglected, or conditions whose impact has been
underestimated, and demonstrate that there are
feasible solutions.
Sponsors, national healthcare authorities,
international agencies and research ethics com-
mittees must also be involved. If sponsors were
required to fund the future provision of effec-
tive interventions, the majority would no longer
support such research. Provision of a success-
ful intervention to the wider community is pri-
marily the responsibility of governments, al-
though there have been contributions from the
pharmaceutical industry. We concluded that the
complexity of the circumstances relating to the
availability of interventions after the comple-
tion of a trial makes it difficult to formulate
general guidance which applies to all different
forms of interventions.  However, there is a duty
on researchers to address the issue before any
research is initiated, and investigators must jus-
tify to the relevant research ethics committee
why the research should be carried out if it is
not thought possible to make a new interven-
tion available to some or all of the host country
population.
Another issue arises after the research if
participants suffer an adverse effect as a con-
sequence of the trial. Clearly, during the study
the researchers have a responsibility to care for
those who may suffer such adverse effects aris-
ing from the research. But in our view, this re-
sponsibility extends also to those who suffer
such adverse effects after the trial is formally
ended, and to those who suffer the chronic con-
sequences of adverse effects experienced dur-
ing the study. The question of compensation for
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those injured or placed at increased risk of harm
in the future as a result of research also needs
to be addressed before the research begins.
One real contribution which researchers and
sponsors may be able to make is to increase the
number of people able to contribute to
healthcare and to assist the development of their
skills and expertise so that there is some poten-
tial for a sustained improvement in healthcare
services after the study is completed. The ex-
pertise to undertake research at local level is
severely limited, with insufficiently trained
personnel and a lack of a critical mass of re-
searchers. It is very important that research in
developing countries is used as a platform for
enhancing the skills of scientists in the local
communities, and there is a need to promote
genuine partnerships to strengthen expertise in
research and institutional development. We rec-
ommended that the development of expertise
in healthcare and research should be an inte-
gral component of all research in developing
countries. Sponsors should ensure provision for
education and training in ethics of all profes-
sionals involved in research.
